Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Dermapen is considered more effective and easier to use than dermaroller and dermastamp for hair loss treatment, though results vary. Dermastamp is affordable but less convenient, while dermapen is more precise but can be bloody.

The conversation discusses using topical exosomes with a derma roller for hair loss. Users also mention minoxidil for treatment.

The user is experimenting with a zinc sulfate and B6 topical solution called "Zix" for hair loss, alongside using a zinc oxide scalp mask and low-level laser therapy (LLLT). They report minimal hair loss after three months of use and are seeking feedback from others who have tried similar treatments.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

A user shared their experience with hair loss treatments, including topical minoxidil, finasteride, RU58841, and microneedling, noting significant hair regrowth except at the hairline. They plan to start oral minoxidil and switch to a combination treatment, while another user mentioned that some miniaturized hairs may not fully recover.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Concerns about the integrity of Dr. Melissa Toyos' marketing for Verteporfin treatment, suggesting photos may be digitally altered. Users express skepticism about the treatment's promotion and results.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

The user is concerned about a thinning spot on their hairline and is considering treatments like minoxidil, microneedling, and dermarolling. They have started using minoxidil despite it not being recommended for their type of hair loss and are seeking advice on other potential solutions.

Dermal incision with verteporfin is being explored as a potential hair loss treatment by dermatologist Melissa Toyos, with promising before-and-after photos shared on social media. The conversation discusses its potential effectiveness compared to other treatments like Minoxidil, Finasteride, and RU58841.

Cheap Indian brands of Minoxidil and Dutasteride are discussed, with recommendations for Lonitab, Minlenth, Mintop, and Duprox by Cipla. Cipla and Dr. Reddys are noted for their strict quality control, but their products can be expensive.

Scalp micropigmentation (SMP) is a debated hair loss solution, with some praising its natural look and low maintenance, while others criticize it for looking unnatural and being a temporary fix. Many prefer traditional hair restoration methods like hair transplants or medications such as finasteride and minoxidil.

The conversation discusses the effectiveness of dermastamps versus dermarollers for hair loss treatment, with some users preferring dermastamps for precision and less hair damage. One user reports using a dermastamp with minoxidil, while others mention the convenience of dermapens and the cost-effectiveness of dermarollers.

A 30-year-old male reports improved hairline after using Minoxidil twice daily, Finasteride 1.25mg daily, and dermarolling weekly to biweekly since July 2025. Users notice positive changes and encourage continued use.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

A user offers an extra bottle of Koshine 0.5% solution for hair loss. The discussion involves interest in trying Pyrilutamide for hair treatment.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

The conversation is about the effectiveness of a hair loss treatment product containing 0.01% Latanoprost, with the user considering trying it as a vehicle for RU58841. The user questions whether the dosage is too low to be effective.

A user experienced worsened hair condition after a PRP session and is considering stopping further sessions. They are using a Dermapen, electric massage, iron, saw palmetto, and plan to start minoxidil, but have had side effects with finasteride and are advised to consider dutasteride under medical supervision.

Nizoral causes scalp and face itchiness and flakes. Piroctone olamine is suggested as an alternative.

The conversation discusses concerns about a receding hairline potentially due to increased DHT from creatine use, with suggestions to try Rogaine. The user plans to seek a professional opinion and notes a family history of early baldness.

The user switched from liquid to foam minoxidil to reduce skin irritation but finds foam harder to apply effectively to the scalp. A suggestion was made to melt the foam into a liquid for easier application.

Verteporfin, combined with microneedling, shows promise for hair regrowth by allowing hair follicles to grow in wounds, but it's expensive and painful. Pai-1 inhibitors may also help prevent hair loss by degrading fibrosis, and some users continue using minoxidil alongside these treatments.